New Drug Update 2010-2011 Faculty Disclaimer - CME Conferences

2 nd Annual Essentials in Primary Care
Fall Conference
Friday, November 11, 2011
Pitavastatin - Livalo
• Mean Change from Baseline to Week 12
Treatment LDL-C Apo B TC TG HDL-C
Pitavastatin 2 mg (n= 307) -39% -30% -28% -16% 6%
Pitavastatin 4 mg (n= 319) -44% -35% -32% -17% 6%
Simvastatin 20 mg (n= 107) -35% -27% -25% -16% 6%
Simvastatin 40 mg (n= 110) -43% -34% -31% -16% 7%
The most frequent adverse effects, occurring in at least 2% of patients
receiving one of the available doses, were myalgia, back pain, diarrhea,
constipation, and pain in extremity.
Pitavastatin - Livalo
• DRUG INTERACTIONS: Several agents
(cyclosporine-avoid, rifampin-max 2mg,
eryrthromycin-max 1 mg, gemfibrozil and
lopinovir/retonavir-caution) have the
potential to interact with the organic anion
transporting polypeptide–mediated uptake of
pitavastatin.
• 1, 2, and 4 mg tablets supplied in bottles of
90 tablets. The cost for all three doses is
$119.00/30 AWP.
Wayne Weart
New Drug Update Part I